GlassScriptPhysician profile
Frank A Parke
NPI 1316035264
$227,507.13
in general payments reported to CMS, 2019-2025
38 companies · $3,690 in 2025
The $3,690 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $28K · 2021: $25K · 2022: $72K · 2023: $25K · 2024: $3,241 · 2025: $3,690.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $11K · Travel and Lodging: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,900.00 |
| Food and Beverage | $10,675.79 |
| Travel and Lodging | $1,644.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $167,915.28 | 2019-2025 | Taltz |
| Amgen INC. | $20,205.74 | 2019-2025 | Avsola, Enbrel, Tavneos |
| Janssen Scientific Affairs, LLC | $19,420.25 | 2019-2020 | |
| Janssen Biotech, INC. | $5,522.10 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $3,476.03 | 2019-2025 | |
| Ucb, INC. | $1,755.72 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,660.59 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,322.85 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $1,219.65 | 2019-2025 | |
| Horizon Therapeutics Plc | $845.58 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $793.15 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $570.24 | 2019-2025 | Actemra |
| Astrazeneca Pharmaceuticals LP | $489.16 | 2021-2025 | Saphnelo |
| Radius Health, INC. | $432.09 | 2019-2025 | Tymlos |
| Tersera Therapeutics LLC | $283.97 | 2022-2023 | Quzyttir |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Parke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.